Holen Sie sich die Stockscreener-App
5.12
2.48%
-0.13
Schlusskurs vom Vortag:
$5.25
Offen:
$5.3
24-Stunden-Volumen:
440.19K
Relative Volume:
1.11
Marktkapitalisierung:
$108.51M
Einnahmen:
$73.62M
Nettoeinkommen (Verlust:
$-138.24M
KGV:
-0.7805
EPS:
-6.56
Netto-Cashflow:
$-99.19M
1W Leistung:
+5.79%
1M Leistung:
-18.47%
6M Leistung:
-64.25%
1J Leistung:
-56.28%
1-Tages-Spanne:
$5.02
$5.3298
1-Wochen-Bereich:
$4.71
$5.3298
52-Wochen-Spanne:
$4.71
$17.80
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
Firmenname
Enanta Pharmaceuticals Inc
Sektor
Branche
Telefon
617 607 0800
Adresse
500 ARSENAL STREET, WATERTOWN, MA
Vergleichen Sie ENTA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
5.12 | 108.51M | 73.62M | -138.24M | -99.19M | -6.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-09 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-08-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-07-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-10-07 | Eingeleitet | Jefferies | Buy |
| 2021-09-09 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-11-24 | Eingeleitet | Evercore ISI | Underperform |
| 2020-08-28 | Fortgesetzt | ROTH Capital | Buy |
| 2020-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-27 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-05-24 | Eingeleitet | Wolfe Research | Outperform |
| 2019-04-23 | Hochstufung | Berenberg | Hold → Buy |
| 2018-12-13 | Eingeleitet | Berenberg | Hold |
| 2018-06-06 | Eingeleitet | ROTH Capital | Buy |
| 2018-02-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | Bestätigt | RBC Capital Mkts | Outperform |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-07-11 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | Bestätigt | Barclays | Underweight |
| 2015-10-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2015-10-23 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
Alle ansehen
Enanta Pharmaceuticals Inc Aktie (ENTA) Neueste Nachrichten
JPMorgan Chase & Co. Increases Stock Position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by JPMorgan Chase & Co. - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Bought by Barclays PLC - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average Target Price from Brokerages - MarketBeat
Enanta stock hits 52-week low at $4.83 amid market challenges - Investing.com Nigeria
Enanta stock hits 52-week low at $4.83 amid market challenges By Investing.com - Investing.com South Africa
Jane Street Group LLC Has $240,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
ENTA (Enanta Pharmaceuticals) Peter Lynch Fair Value : N/A (As of Jan. 11, 2025) - GuruFocus.com
Enanta stock hits 52-week low at $5.29 amid market challenges - Investing.com Nigeria
Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by Barclays PLC - Defense World
Geode Capital Management LLC Has $4.95 Million Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
(ENTA) Technical Pivots with Risk Controls - Stock Traders Daily
Enanta stock touches 52-week low at $5.68 amid market challenges - Investing.com Australia
Enanta stock touches 52-week low at $5.68 amid market challenges By Investing.com - Investing.com South Africa
Brokers Issue Forecasts for ENTA Q1 Earnings - Defense World
Equities Analysts Offer Predictions for ENTA Q1 Earnings - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
FY2029 Earnings Estimate for ENTA Issued By HC Wainwright - Defense World
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $17.25 Average PT from Brokerages - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $18.00 by Analysts at HC Wainwright - Defense World
Equities Analysts Set Expectations for ENTA FY2029 Earnings - MarketBeat
Pfizer prevails in Enanta patent case over Covid-19 drug By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals stock remains Buy-rated with Phase 2 data driving model revisions - Investing.com Australia
When (ENTA) Moves Investors should Listen - Stock Traders Daily
Pfizer prevails in Enanta patent case over Covid-19 drug - Investing.com India
Pfizer Gets Enanta Patent Voided in Case Over Paxlovid Royalties - Bloomberg Law
Enanta Pharmaceuticals (ENTA) Appeals Court Ruling in Patent Dis - GuruFocus.com
HC Wainwright Cuts Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target to $18.00 - MarketBeat
Enanta to appeal as Pfizer wins Paxlovid patent ruling - MSN
Enanta stock slips as Pfizer wins Paxlovid patent (PFE:NYSE) - Seeking Alpha
Enanta Pharmaceuticals to Appeal Ruling in Patent Infringement Case Against Pfizer - MarketWatch
Enanta Pharma Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Enanta Loses Key Patent Battle Against Pfizer Over COVID Drug Paxlovid in Court Ruling - StockTitan
Enanta Pharmaceuticals (ENTA) Moves 7.2% Higher: Will This Strength Last? - Yahoo Finance
Fmr LLC Purchases 7,839 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 27,597 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Charles Schwab Investment Management Inc. Sells 1,649 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) - Defense World
Enanta Pharmaceuticals' SWOT analysis: RSV pipeline progress buoys stock outlook - Investing.com
(ENTA) Technical Data - Stock Traders Daily
Enanta stock touches 52-week low at $6.36 amid market challenges - Investing.com Canada
FY2025 Earnings Estimate for ENTA Issued By Leerink Partnrs - Defense World
Finanzdaten der Enanta Pharmaceuticals Inc-Aktie (ENTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):